October 2025

Aspire Mining Limited reports significant progress on its Ovoot Coking Coal Project, securing exclusive marketing rights and aligning infrastructure development with government-backed transport projects.

Austral Gold’s Q3 report reveals a sharp production drop at Guanaco following a fatal accident, prompting a downward revision of 2025 output and cost hikes, while Casposo’s refurbishment signals a new growth phase.

Argenica Therapeutics reports ARG-007 is safe in acute ischemic stroke patients and shows promising efficacy signals in a high-risk subgroup, paving the way for a focused Phase 2b trial.

DXN Limited reports a sharp revenue decline in Q1 FY26 due to client-driven project deferrals but highlights a robust $11.9 million backlog and the imminent launch of its first Data Centre as a Service site.

West Cobar Metals reports significant progress across its WA and NSW projects, with promising assay results for rare earths and base metals, alongside strategic engagement in the US market and a recent $1.25 million capital raise.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Novatti Group has achieved positive operating cashflow and EBITDA for the September quarter, driven by strategic revenue reforms and new commercial contracts with major clients.

Prairie Lithium has fast-tracked its flagship Saskatchewan lithium project by initiating fabrication of a commercial-scale extraction unit and securing vital rail access, supported by a US$5 million non-dilutive capital raise and a promising offtake agreement.

Xstate Resources has secured $3.82 million through a two-tranche capital raising to advance appraisal and production testing at its Diona-1 well in Queensland, positioning the company for critical flow testing and further exploration.

Livium Ltd has completed its strategic pivot to focus on recycling clean energy waste, reporting solid Q1 FY26 results and securing a significant capital raise to fuel expansion into battery, solar panel, and rare-earth element recycling.

SRJ Technologies has landed a US$269,000 contract to supply its BoltEx flange integrity solution to a leading FPSO operator offshore Guyana, marking a strategic foothold in a key offshore energy market.

Savannah Goldfields Limited has completed key maintenance and recommissioning at its Georgetown Gold Processing Plant, targeting a first gold pour in early November 2025. Mining at Big Reef is set to begin shortly, with Agate Creek operations planned for next year.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

Integral Diagnostics reports a robust FY25 with revenue climbing 33.7% to $628 million, driven by successful Capitol Health merger integration and strong growth in teleradiology. CEO Dr Ian Kadish announces retirement after eight transformative years.

Green360 Technologies has independently verified its Eco-Clay product as a high-performance, low-carbon cement substitute made from kaolin waste, poised to disrupt Australia’s $3.5 billion cement market.

Acusensus Limited has secured a significant expansion of its contract with Queensland’s Department of Transport and Main Roads, doubling its trailer-based speed enforcement units with a $16.6 million deal set to roll out from late 2025.

BSA Limited’s Q1 FY2026 results reveal a sharp revenue drop following the expiration of its key nbn contract, alongside a major workforce reduction and strategic pivot.

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

Pathkey.AI reports strong validation of its TrialKey AI platform’s predictive accuracy and announces key leadership changes as it advances toward commercial scale.

Mach7 Technologies reports a modest rise in recurring revenue alongside a comprehensive commercial transformation, positioning itself for growth in AI-driven medical imaging.

Top End Energy has unveiled a significant prospective hydrogen resource in Kansas and strengthened its U.S. market presence with new OTCQB listings, while advancing strategic discussions in Australia’s Beetaloo Basin.